I contain multitudes – new frontiers in human somatic genetics (Farber Lectureship)
As part of our LMP Seminar Series and for the Farber Lectureship, we are delighted to welcome our speaker:
Dr. Dan Landau MD, PhD
Professor, Division of Hematology and Medical Oncology
Professor, Systems and Computational Biology
Weill Cornell Medicine
Talk title: "I contain multitudes – new frontiers in human somatic genetics"
Hosted by
Dr. Gavin Wilson, PhD & Dr. Rod Bremner, PhD
How to join
The event will be in person, no need to register. Students and trainees must attend in person.
For faculty members who need to attend remotely, please register to receive the zoom link. Registration must be received by noon on Tuesday.
If you have any questions, please contact lmp.chairadmin@utoronto.ca for more details.
Wednesday, April 8, 2026
11 am - 12 pm
MSB 2170
Medical Sciences Building
University of Toronto
1 King’s College Circle
Toronto, ON M5S 1A8
Details are sent to the LMP community in the Friday events bulletin.
Speaker bio: Dr. Dan Landau MD, PhD
Dr. Landau is Professor of Medicine in the Division of Hematology and Medical Oncology and Professor of Systems and Computational Biology at Weill Cornell Medicine. He currently serves as Director of the McMillan Center for the Non-Coding Cancer Genome at the New York Genome Center and as Co-Director of the Center for Excellence in Genomic Science.
Dr. Landau received his B.S. from Tel Aviv University, his M.D. from the Sackler School of Medicine at Tel Aviv University, and his Ph.D. from Paris Diderot University . He completed his residency in Internal Medicine and fellowship in Hematology and Medical Oncology at Yale University, followed by postdoctoral training at the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT.
Dr. Landau’s research integrates clinical oncology, genomics, and computational biology to define the genetic and epigenetic mechanisms that drive cancer evolution. His laboratory develops and applies single-cell multi-omic technologies, high-resolution sequencing approaches, and machine learning methods to map genotype-to-phenotype relationships, characterize clonal dynamics, and enable ultra-sensitive detection of cancer through liquid biopsy . His work has advanced understanding of tumor heterogeneity, clonal hematopoiesis, and therapeutic resistance, and has been published in leading journals including Nature, Cell, Cancer Cell, Nature Genetics, Nature Medicine, and Nature Biotechnology.
Dr. Landau has received numerous honors, including the NIH Director’s New Innovator Award, the Pershing Square Sohn Prize for Young Investigators in Cancer Research, the Vallee Scholar Award, the Sontag Foundation Distinguished Scientist Award, and the Mark Foundation Emerging Leader Award . He is an elected member of the American Society for Clinical Investigation and serves on the editorial boards of Cancer Cell and Blood . He is also a co-founder of C2i Genomics and Montage Bio.
